Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026)

Caris Life Sciences' (CAI) quarterly Asset Utilization Ratio came in at 0.79 in Q1 2026, up 3.05% quarter-over-quarter from 0.77 in Q4 2025.

Caris Life Sciences (CAI) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Caris Life Sciences' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.79 for Q1 2026.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.79 in Q1 2026; TTM through Mar 2026 was 0.79, a N/A change from a year earlier, with the FY2025 full-year figure at 1.11, changed N/A from the prior year.
Asset Utilization Ratio climbed to 0.79 in Q1 2026 per CAI's latest filing, from 0.77 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.79 in Q1 2026 and bottomed at 0.67 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Caris Life Sciences	4.42 Bn	3.60 Bn	214.23 Mn	0.79

Download Data